![]() Performed IP due diligence for a syndicate of venture capital firms in connection with an investment in a protein therapeutics company.Performed IP due diligence for a venture capital firm in connection with an investment in a nucleic acid instrumentation company.Counsels the client on patent strategy, portfolio development, licensing activities, and general intellectual property matters. Represents a private biotechnology company developing novel protein therapeutics. ![]() and around the world and coordinated activities with collaboration partners. During that period, drafted and prosecuted a broad patent portfolio in the U.S. Represents a public biotechnology company for over 10 years on a variety of intellectual property matters.Represented the underwriters in connection with over 50 public offerings, including initial public offerings or follow-on offerings for bluebird bio, Sage Therapeutics, Proteostasis Therapeutics, Avexis, Dimension Therapeutics, Biohaven Pharmaceutical Holdings Company Ltd., Clementia Pharmaceuticals, Therapeutics MD, and Quanterix.Helped our client evaluate the patent portfolios for two target companies, identify potential issues, and develop appropriate remediation strategies. Represents a publicly traded biotechnology company in connection with their acquisition activities. ![]() ![]()
0 Comments
Leave a Reply. |